Cindy NEUZILLET

Cindy Neuzillet is M.D., Ph.D., responsible for the coordination of GI Oncology in the Medical Oncology Department at Curie Institute, Saint Cloud, Versailles Saint Quentin University, and Ambroise Paré Hospital, AP-HP, Boulogne.

She graduated and was board certified in Hepato-Gastro-Enterology in 2013 (D.E.S., Paris VII Diderot University, Beaujon Hospital) and then in Oncology (D.E.S.C.) in 2014. She has been working on pancreatic cancer since her medical studies under the supervision of Prof. Pascal Hammel and Prof. Eric Raymond (Beaujon Hospital); she obtained her M.D. thesis working on c-Met expression in resected pancreatic cancer and her Master 2 studying the effects of MEK inhibition in pancreatic cancer cell lines. After an Oncology fellowship at Beaujon and Henri Mondor University Hospitals (Prof. E. Raymond’s and Prof. C. Tournigand’s Departments, 2013-2015), she spent 18 months in Prof. Hemant Kocher’s lab, Barts Cancer Institute, Queen Mary University of London, and then 18 months in Dr. Corinne Bousquet’s lab, Center for Cancer Research of Toulouse, for her Ph.D. (2015-2018), aiming at establishing a classification of cancer-associated fibroblasts in pancreatic cancer. This work involved international collaborations between French, UK, German, Turkish and Australian teams.

Since 2014, she has been investigator in AGEO, GERCOR and PRODIGE studies. She is a member of the GERCOR “Non-colorectal GI Cancers” and “Supportive care” working groups and of the PRODIGE “Pancreatic and Biliary Tract Cancers” and “Neuroendocrine Tumours” working groups. Since 2017, she is the leader of the GERCOR “Young/Translational” working group (DigIN). She is national PI of the PRODIGE GERCOR Phase IIR immunotherapy studies TEDOPaM-PRODIGE 63 (OSE2101 vaccine with or without nivolumab immunotherapy in pancreatic cancer as maintenance strategy after FOLFIRINOX induction chemotherapy, NCT03806309) and IMMUNO-BIL-PRODIGE 57 (durvalumab plus tremelimumab combination immunotherapy with or without weekly paclitaxel in advanced biliary tract cancers in 2nd line, NCT03704480). She is also member of the AFSOS (French Association for Supportive Care) Expert group for “Physical activity and Cancer” and coordinates two multicenter randomized clinical trials evaluating physical activity interventions in patients with advanced (APACaP GERCOR Trial, NCT02184663) or resectable pancreatic cancer (APACaPOp-PRODIGE 56 Trial, NCT03400072). She is leader of the Working Group for French guidelines for Physical Activity in GI Cancers and member of the Working Group for Pancreatic Cancer management (SNFGE – TNCD). Finally, she is vice President of the French Pancreatic Club (CFP) and President of the French Association for the Study of Biliary Tract Cancer and Diseases (ACABi).

 

Top